Acute Ischemic StrokePERSISTNCT06053021
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
A study testing aspirin, clopidogrel, cilostazol, and dipyridamole in people with Acute Ischemic Stroke and Thrombocytopenia, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Ischemic Stroke, Thrombocytopenia
- What is being tested?
- aspirin, clopidogrel, cilostazol, and dipyridamole
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,200 participants
- Where
- 1 siteChina
- Study dates
- 15 Sep 2023to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18 years old
- Acute ischemic stroke or transient ischemic attack with onset < 7 days
- The last blood routine test before enrollment indicates platelet count < 100 x 10^9 and > 30 x 10^9
Who cannot join
- Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury
- Indications for anticoagulation therapy, e.g. atrial fibrillation
- Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
- Have or plan to receive CEA or CAS in the following 3 months
- Life expectancy less than 1 year
- Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding
- Pregnant or lactating women
- Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou
Min Lou, PhD, 8657187784811, loumingxc@vip.sina.com
About this study
Official title: Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Read the detailed description
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
- Conditions
- Acute Ischemic Stroke, Thrombocytopenia
- Being tested
- aspirin, clopidogrel, cilostazol, and dipyridamole
- Medical subject headings
- Ischemic Stroke, Thrombocytopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
aspirin, clopidogrel, cilostazol, and dipyridamoleDrug
Also called Antiplatelet Agents
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole. Receives: Drug: aspirin, clopidogrel, cilostazol, and dipyridamole |
What is being measured
The primary outcome is the main question the study is designed to answer.
90-day Composite events
Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment
Measured: 90 days
Secondary outcomes (8)
90-day ischemic stroke
Ischemic stroke within 90 days after enrollment
Measured: 90 days
90-day hemorrhagic stroke
Hemorrhagic stroke within 90 days after enrollment
Measured: 90 days
90-day myocardial infarction
Myocardial infarction within 90 days after enrollment
Measured: 90 days
90-day major extracranial hemorrhage
Major extracranial hemorrhage within 90 days after enrollment
Measured: 90 days
90-day non-major bleeding
Non-major bleeding within 90 days after enrollment
Measured: 90 days
90-day vascular death
Vascular death within 90 days after enrollment
Measured: 90 days
90-day all-cause death
All-cause death within 90 days after enrollment
Measured: 90 days
Discharge mRS
Modified Rankin scale at discharge
Measured: Through hospitalization, an average of 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2023
- Study start15 Sep 2023
- Primary completion1 Oct 2025 (estimated)
- Study completion1 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06053021
- Sponsor's protocol ID
- PERSIST
- Acronym
- PERSIST
- Status last verified
- Sep 2023
- First submitted
- 11 Sep 2023
- Last updated
- 18 Oct 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia
- ClinicalTrials.gov ID
- NCT06053021
- Acronym / sponsor ID
- PERSIST / PERSIST
- Conditions
- Acute Ischemic Stroke, Thrombocytopenia
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Study start
- 15 Sep 2023 (actual)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 1 Jan 2026 (estimated)
- First posted
- 25 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Detailed description
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Drug: aspirin, clopidogrel, cilostazol, and dipyridamoleParticipants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age > 18 years old
- Acute ischemic stroke or transient ischemic attack with onset < 7 days
- The last blood routine test before enrollment indicates platelet count < 100 x 10^9 and > 30 x 10^9
Key exclusion criteria (8 listed)
- Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury
- Indications for anticoagulation therapy, e.g. atrial fibrillation
- Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
- Have or plan to receive CEA or CAS in the following 3 months
- Life expectancy less than 1 year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| aspirin, clopidogrel, cilostazol, and dipyridamoleAlso: Antiplatelet AgentsParticipants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole. | Drug | Intervention |
Primary outcome
90-day Composite events
Time frame: 90 days
Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment
8 secondary outcomes
90-day ischemic stroke
Time frame: 90 days
90-day hemorrhagic stroke
Time frame: 90 days
90-day myocardial infarction
Time frame: 90 days
90-day major extracranial hemorrhage
Time frame: 90 days
90-day non-major bleeding
Time frame: 90 days
90-day vascular death
Time frame: 90 days
90-day all-cause death
Time frame: 90 days
Discharge mRS
Time frame: Through hospitalization, an average of 7 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2023.
- Individual participant dataSharing planned: No
Related trials for Acute Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Not yet recruitingPhase 2/3
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing aspirin, clopidogrel, cilostazol, and dipyridamole in people with Acute Ischemic Stroke and Thrombocytopenia, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Min Lou, PhD (+8613958007213, loumingxc@vip.sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
90-day Composite events (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2023.